MannKind Corp
MNKD
$4.13
Share price
0.49%
Change (1 day)
0.73%
Change (1 year)
Categories
Revenue for MannKind Corp (MNKD)
Revenue in 2023 (TTM): $0.15 B
According to MannKind Corp's latest financial reports the company's current revenue (TTM) is $0.15 B. In 2022 the company made a revenue of $99.77 M an increase over the years 2021 revenue that were of $75.44 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for MannKind Corp from 2009 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $0.15 B | 58.49% |
| 2022 | $99.77 M | 32.25% |
| 2021 | $75.44 M | 15.81% |
| 2020 | $65.14 M | 3.34% |
| 2019 | $63.03 M | 126.28% |
| 2018 | $27.85 M | 137.2% |
| 2017 | $11.74 M | -93.28% |
| 2016 | $0.17 B | |
| 2015 | N/A | |
| 2014 | N/A | |
| 2013 | N/A | -100% |
| 2012 | $0.03 M | -30% |
| 2011 | $0.05 M | -46.24% |
| 2010 | $0.09 M | |
| 2009 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $77.94 B | 49,193.90% | 🇺🇸 USA |
 Novo Nordisk NVO | $28.68 B | 18,042.17% | 🇩🇰 Denmark |
 Eli Lilly LLY | $29.51 B | 18,566.40% | 🇺🇸 USA |
 Merck MRK | $58.31 B | 36,777.45% | 🇺🇸 USA |
 Halozyme Therapeutics HALO | $0.77 B | 389.28% | 🇺🇸 USA |
 Nektar Therapeutics
NKTR | $87.74 M | -44.51% | 🇺🇸 USA |